Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study.
腎臟疾病和2型糖尿病患者使用鈉葡萄糖共同轉運蛋白2抑製劑的安全性:美國人口基礎的世代研究。
Clin J Am Soc Nephrol 2024-05-02
Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong.
比較鈉葡萄糖共同轉運蛋白2抑制劑和二肽基胜肽酶-4抑制劑對香港新發抑鬱症的影響:一項傾向性配對研究。
Acta Diabetol 2023-05-22
Risk of New-onset Stroke in Patients with Type 2 Diabetes with Chronic Kidney Disease on Sodium-glucose Co-transporter-2 Inhibitor Users.
2型糖尿病合併慢性腎臟病使用鈉葡萄糖共同轉運蛋白2抑製劑的患者中新發中風風險。
Transl Stroke Res 2023-07-13
Real-world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium-glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score-matched model analysis in Japan.
與二甲双胍相比,日本患有第2型糖尿病患者使用鈉葡萄糖共同轉運蛋白2抑制劑的實際心血管疾病風險:一項傾向性配對模型分析。
J Diabetes Investig 2023-10-23
Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
第二型糖尿病患者中鈉葡萄糖共同轉運蛋白2抑制劑與腎結石風險。
JAMA Intern Med 2024-03-05
Comparisons of the risks of new-onset prostate cancer in type 2 diabetes mellitus between SGLT2I and DPP4I users: a population-based cohort study.
SGLT2I 與 DPP4I 使用者中,2 型糖尿病新發前列腺癌風險的比較:一項基於人群的隊列研究。
Diabetes Metab 2024-08-25
Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study.
在40-69歲的2型糖尿病成人中,啟用鈉-葡萄糖共轉運蛋白-2抑制劑與二肽基肽酶-4抑制劑後癡呆風險的比較:基於人群的隊列研究。
BMJ 2024-08-28
Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks.
鈉-葡萄糖共轉運蛋白 2 抑制劑與 2 型糖尿病老年患者新發癡呆風險及全因死亡率的關聯:基於 TriNetX 美國合作網絡的回顧性隊列研究。
Diabetes Obes Metab 2024-09-09